Clinical trial NCT00916656: Fibrinogen Concentrate (Human) - Efficacy and Safety Study
Official title: Efficacy and Safety of Fibrinogen Concentrate (Human) (FCH) for On-demand Treatment of Acute Bleeding in Subjects With Congenital Fibrinogen Deficiency
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE3
Conditions: Afibrinogenemia
Hypofibrinogenemia
Fibrinogen Deficiency
Keywords: Congenital fibrinogen deficiency
Lead sponsor: CSL Behring
Sponsor class: INDUSTRY
First posted: 2009-06-09
Enrollment: 0
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This is a multinational, multicenter, prospective, open-label historically controlled Phase IIIb non-inferiority clinical trial on the efficacy and safety of Fibrinogen Concentrate (Human).

It is estimated that 150-300 patients in the U.S. suffer from afibrinogenemia. Substitution with cryoprecipitate or alternative treatments have limited safety and efficacy.

The primary purpose of the study is to demonstrate the hemostatic efficacy of Fibrinogen Concentrate (Human) by adequately controlling acute bleeding (spontaneous or after trauma) in patients with congenital fibrinogen deficiency (afibrinogenemia and hypofibrinogenemia). Cryoprecipitate hemostatic efficacy data from a retrospective physician survey will be used as a historical control.


Eligibility criteria: Inclusion Criteria:

* Documented congenital fibrinogen deficiency (afibrinogenemia and hypofibrinogenemia), expected to require treatment for bleeding
* Presenting with an episode of acute bleeding (either spontaneous or after trauma) not requiring surgery
* Provide informed consent

Exclusion Criteria:

* Life expectancy \< 6 months
* Bleeding disorder other than congenital fibrinogen deficiency, but including dysfibrinogenemia
* Treatment with any investigational medicinal product (IMP) in the 30 days prior to enrollment
* Treatment with any fibrinogen concentrate or other fibrinogen containing blood product in the 2 weeks prior to enrollment
* Treatment with any coagulation active drug (i.e., non-steroidal-antirheumatics, warfarin, cumarin derivates, platelet aggregation inhibitors) in 1 week prior to enrollment or as a planned or expected medication during the time period from Day 1 until 24 hours after the last FCH infusion
* Presence or history of hypersensitivity to FCH
* Presence or history of deep vein thrombosis or pulmonary embolism within 1 year prior to enrollment
* Presence or history of arterial thrombosis within 1 year prior to enrollment
* Presence or history of hypersensitivity to human plasma proteins
* Presence or history of esophageal varicose bleeding
* End stage liver disease (i.e., Child Pugh score B or C)
* Planned or expected surgery (i.e., for bleedings from aneurysm or splenic rupture)
* Pregnancy, or an intention to become pregnant during the study
* Currently breast-feeding, or with the intention of breast-feeding during the study
* Human immunodeficiency virus (HIV) positive
* Polytrauma, present or within 6 months prior to enrollment
* Suspicion of an anti-fibrinogen inhibitor as indicated by previous in-vivo recovery (IVR), if available (\< 0.5 (mg/dL)/(mg/kg))
* Previous inclusion and treatment in the prospective part of the study
* Participation in any clinical study in the 30 days prior to enrollment

Primary outcomes:
measure: Clinical assessment of hemostatic efficacy
timeFrame: 24 hours after last infusion or at Day 14 (whichever occurs first)
Secondary outcomes:
measure: Maximum clot firmness (MCF)
timeFrame: Prior to and 60 minutes after the end of each infusion
measure: Fibrinogen plasma level
timeFrame: 60 minutes, 3 hours, 6 hours, and 12 hours after the end of the first infusion; before and 60 minutes after each subsequent infusion
measure: In vivo recovery of fibrinogen
timeFrame: 60 minutes, 3 hours, 6 hours and 12 hours after the end of the first infusion; before and 60 minutes after the end of each subsequent infusion and at the time of the overall clinical assessment of hemostatic efficacy
measure: Virus safety markers
timeFrame: Day 1 to Day 45
Other outcomes:
Locations:
Study officials:
affiliation: CSL Behring
name: Program Director, Clinical R&D
role: STUDY_DIRECTOR
References: